SpringerLink
Log in

Safety, Tolerability and Pharmacokinetics of the Serotonin 5-HT6 Receptor Antagonist, SUVN-502, in Healthy Young Adults and Elderly Subjects

  • Original Research Article
  • Published:
Clinical Drug Investigation Aims and scope Submit manuscript

Abstract

Background and Objective

SUVN-502, a selective 5-HT6 receptor antagonist, was found to be active in preclinical models of cognitive deterioration suggesting a potential role in the treatment of dementia related to Alzheimer’s disease. The objective of this study was to characterize the safety, tolerability and pharmacokinetics of SUVN-502 in healthy young adults and elderly subjects following single and multiple oral doses.

Methods

Single doses (5, 15, 50, 100 and 200 mg SUVN-502) and multiple doses (50, 100 and 130 mg SUVN-502 once daily for 7 days) were evaluated in healthy young adults and multiple doses (50 and 100 mg SUVN-502 once daily for 14 days) were evaluated in elderly subjects using randomized, double-blind, placebo-controlled, dose-escalating study designs. The effect of food, gender and age on SUVN-502 pharmacokinetics (100 mg single dose) was evaluated using an open-label, two-period, randomized, fed and fasted in a crossover design. SUVN-502 and M1 (major metabolite of SUVN-502) were monitored using validated analytical methods.

Results

SUVN-502 is safe and well tolerated up to the highest tested single dose of 200 mg in healthy young adults and multiple doses up to 130 mg for 7 days and 100 mg for 14 days in healthy young adults and elderly subjects, respectively. Exposures of SUVN-502 and M1 were more than dose-proportional over the evaluated dose range. Food and gender did not have a clinically meaningful effect on SUVN-502 exposure. The mean SUVN-502 total (AUC0–∞, and AUC0–last) and peak exposures (Cmax) were 2.9- and 2.2-fold higher, respectively, in elderly subjects compared to young subjects. Steady-state was achieved for SUVN-502 and M1 within 7 days after once-daily dosing of SUVN-502.

Conclusions

SUVN-502 exhibited an acceptable safety, tolerability and pharmacokinetic profile in healthy young adults and elderly subjects. Based on the above results, 50 and 100 mg once-daily doses of SUVN-502 were advanced to Phase 2 evaluation in patients with moderate AD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price includes VAT (Germany)

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Francis PT, Palmer AM, Snape M, Wilcock GK. The cholinergic hypothesis of Alzheimer’s disease: a review of progress. J Neurol Neurosurg Psychiatry. 1999;66(2):137–47.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Thompson S, Lanctot KL, Herrmann N. The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer’s disease. Expert Opin Drug Saf. 2004;3:425–40.

    Article  CAS  PubMed  Google Scholar 

  3. Schneider LS, Dagerman KS, Higgins JP, McShane R. Lack of evidence for the efficacy of memantine in mild Alzheimer disease. Arch Neurol. 2011;68:991–8.

    Article  PubMed  Google Scholar 

  4. Nirogi R, Shinde A, Kambhampati RS, Mohammed AR, Saraf SK, Badange RK, et al. Discovery and development of 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole dimesylate monohydrate (SUVN-502): a novel, potent, selective and orally active serotonin 6 (5-HT6) receptor antagonist for potential treatment of Alzheimer’s disease. J Med Chem. 2017;60(5):1843–59.

    Article  CAS  PubMed  Google Scholar 

  5. Nirogi R, Kandikere V, Mudigonda K, Bhyrapuneni G, Shinde A, Kambhampati R, Jayarajan P, Abraham R, Mohamad SM, Muddana N, Benade V, Saralaya R. SUVN-502: a potent and selective 5-HT6 antagonist, potential drug for the treatment of Alzheimers disease. Alzheimer’s Dement. 2011;7(4):S659.

    Article  Google Scholar 

  6. Vishwakarma SL, Abraham R, Jayarajan P, Shirsath VS, Nirogi RV. Active metabolite M1 of SUVN-502: efficacy profiling in rodent models of cognition. Neuroscience. 26th annual meeting of Society for Neuroscience (plus poster). Abstract 666; 2006.

  7. ICH Harmonized Tripartite Guideline, guideline for good clinical practice, E6 (R1), Current Step 4 version, dated 10 June 1996.

  8. Nirogi R, Ajjala DR, Aleti R, Rayapati L, Pantangi HR, Boggavarapu RK. Padala NSP development and validation of sensitive LC–MS/MS method for the quantification of SUVN-502 and its metabolite and its application for first in human pharmacokinetic study. J Pharm Biomed Anal. 2017;145:423–30.

    Article  CAS  PubMed  Google Scholar 

  9. Kinirons MT, O’Mahony MS. Drug metabolism and ageing. Br J Clin Pharmacol. 2004;57(5):540–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Association Alzheimer’s. 2017 Alzheimer’s disease facts and figures. Alzheimers Dement. 2017;13(4):325–73.

    Article  Google Scholar 

Download references

Acknowledgements

The authors wish to acknowledge the principal investigators, Seiberling M, Swiss Pharma contract, Lettenweg, Switzerland and Thomas Murtaugh, Quintiles Phase I services LLC, Overland Park, for their support in the conduct of the studies reported in this manuscript. The authors acknowledge Venkateswarlu Jasti, CEO, Suven Life Sciences Ltd, for his moral and financial support.

Author information

Authors and Affiliations

  1. Discovery Research, Suven Life Sciences Ltd, Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad, 500034, India

    Ramakrishna Nirogi, Koteshwara Mudigonda, Gopinadh Bhyrapuneni, Nageswara Rao Muddana, Vinod Kumar Goyal, Santosh Kumar Pandey & Raghava Choudary Palacharla

Authors
  1. Ramakrishna Nirogi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Koteshwara Mudigonda
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gopinadh Bhyrapuneni
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Nageswara Rao Muddana
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Vinod Kumar Goyal
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Santosh Kumar Pandey
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Raghava Choudary Palacharla
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ramakrishna Nirogi.

Ethics declarations

Conflicts of Interest

All authors are employees of Suven Life Sciences Ltd, and are responsible for the content and writing of this manuscript.

Funding

The Phase I study was funded by Suven Life Sciences Ltd, the owner of the compound.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 30 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nirogi, R., Mudigonda, K., Bhyrapuneni, G. et al. Safety, Tolerability and Pharmacokinetics of the Serotonin 5-HT6 Receptor Antagonist, SUVN-502, in Healthy Young Adults and Elderly Subjects. Clin Drug Investig 38, 401–415 (2018). https://doi.org/10.1007/s40261-018-0618-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40261-018-0618-4

Search

Navigation